GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (OTCPK:RNUGF) » Definitions » Construction In Progress

ReNeuron Group (ReNeuron Group) Construction In Progress : $0.00 Mil (As of Sep. 2023)


View and export this data going back to 2006. Start your Free Trial

What is ReNeuron Group Construction In Progress?


ReNeuron Group Construction In Progress Historical Data

The historical data trend for ReNeuron Group's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Construction In Progress Chart

ReNeuron Group Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ReNeuron Group Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ReNeuron Group Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


ReNeuron Group (ReNeuron Group) Business Description

Traded in Other Exchanges
Address
Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.